By analyzing the frequency of CD14+HLA-DRlow/−Co-receptorlow/− Mo-MDSCs in the peripheral blood of patients with MBC we show that Mo-MDSCs significantly correlate to estrogen receptor (ER)-negative disease, liver- and bone metastases, and de novo MBC (metastatic disease at initial diagnosis). This evidence concerns the gene ESR1 and metastatic neoplasm.